http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1812061-A2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd1fcf383108255c0c37f8a99d0df33f |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-4291 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
filingDate | 2005-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_219df6569ecf340d664f127eef57889f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0569e6db21673d656a1ad80bdfc41df6 |
publicationDate | 2007-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-1812061-A2 |
titleOfInvention | Treatment and prevention of hypersensitivity and/or anaphylaxis with anti-ige antibodies in patients receiving replacement therapy |
abstract | The present invention relates generally to a method of treatment and/or prevention of hypersensitivity including anaphylaxis in patients receiving replacement therapy molecules that elicit an IgE-mediated response by administering an anti-IgE antibody or a binding fragment thereof. Anti-IgE antibodies inhibit IgE-mediated allergic reactions in the mammals and can also lower the risk of an anaphylactic reaction to a replacement therapy molecule. The administration of anti-IgE antibodies over time also downregulates the high-affinity IgE receptor, further decreasing the risk of hypersensitivity and/or anaphylaxis. The anti-IgE antibody binds to circulating or serum IgE and/or membrane form IgE on B-cells, but not to IgE bound to mast cells or basophils, as this may cause crosslinking. This method also reduces the dose and/or frequency of administration of the replacement therapy molecule by reducing or eliminating neutralizing IgE antibodies specific for the replacement therapy molecule. |
priorityDate | 2004-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 605.